The post 94% of Strategy’s bitcoin buys since August were from diluting MSTR appeared on BitcoinEthereumNews.com. This morning, Strategy founder Michael Saylor announced more bitcoin (BTC) purchases funded from direct dilution of his MSTR shareholders. Despite MSTR’s underperformance relative to BTC, Saylor has refused to reinstate the July 31 ban on common share dilution. On July 31, 2025, Strategy provided clear guidance to its common shareholders: “We will not issue MSTR below 2.5x mNAV except to pay interest and dividends.” Just two weeks later, on August 18, however, the company revised its promise to dilute MSTR “when otherwise deemed advantageous to the company.” Strategy and Saylor have taken full advantage of that revoked guidance in the past six weeks. Specifically, the company has diluted MSTR common shareholders by 3,278,660 shares in order to spend $1,132,700,000 buying about 10,010 BTC.  Although Strategy is a BTC treasury company valued based on its ability to accrete BTC for shareholders, those dilutive purchases haven’t helped its stock outperform this benchmark. Since its $363.60 closing price on August 18, MSTR has declined more than 10% as of publication time. Over the same time period, BTC has only declined 2%. In other words, MSTR underperformed BTC by an embarrassing 800 basis points since it reintroduced its dilutive, at-the-market (ATM) offerings. From August 18-24, Strategy diluted MSTR by 875,301 shares for $309.9 million in net proceeds. From August 26-September 1, MSTR diluted by 1,237,000 shares for $425.3 million in net proceeds. During September 2-7, Strategy diluted MSTR with another 591,606 shares for $200.5 million in net proceeds. From September 8-21, the company diluted MSTR by 227,401 shares for $80.6 million in net proceeds. Most recently, the company disclosed 347,352 shares for $116.4 million in net proceeds from September 22-28. Almost all of those proceeds went to buying BTC. Including the above MSTR dilution plus other fundraises such as preferred share sales, the company… The post 94% of Strategy’s bitcoin buys since August were from diluting MSTR appeared on BitcoinEthereumNews.com. This morning, Strategy founder Michael Saylor announced more bitcoin (BTC) purchases funded from direct dilution of his MSTR shareholders. Despite MSTR’s underperformance relative to BTC, Saylor has refused to reinstate the July 31 ban on common share dilution. On July 31, 2025, Strategy provided clear guidance to its common shareholders: “We will not issue MSTR below 2.5x mNAV except to pay interest and dividends.” Just two weeks later, on August 18, however, the company revised its promise to dilute MSTR “when otherwise deemed advantageous to the company.” Strategy and Saylor have taken full advantage of that revoked guidance in the past six weeks. Specifically, the company has diluted MSTR common shareholders by 3,278,660 shares in order to spend $1,132,700,000 buying about 10,010 BTC.  Although Strategy is a BTC treasury company valued based on its ability to accrete BTC for shareholders, those dilutive purchases haven’t helped its stock outperform this benchmark. Since its $363.60 closing price on August 18, MSTR has declined more than 10% as of publication time. Over the same time period, BTC has only declined 2%. In other words, MSTR underperformed BTC by an embarrassing 800 basis points since it reintroduced its dilutive, at-the-market (ATM) offerings. From August 18-24, Strategy diluted MSTR by 875,301 shares for $309.9 million in net proceeds. From August 26-September 1, MSTR diluted by 1,237,000 shares for $425.3 million in net proceeds. During September 2-7, Strategy diluted MSTR with another 591,606 shares for $200.5 million in net proceeds. From September 8-21, the company diluted MSTR by 227,401 shares for $80.6 million in net proceeds. Most recently, the company disclosed 347,352 shares for $116.4 million in net proceeds from September 22-28. Almost all of those proceeds went to buying BTC. Including the above MSTR dilution plus other fundraises such as preferred share sales, the company…

94% of Strategy’s bitcoin buys since August were from diluting MSTR

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

This morning, Strategy founder Michael Saylor announced more bitcoin (BTC) purchases funded from direct dilution of his MSTR shareholders.

Despite MSTR’s underperformance relative to BTC, Saylor has refused to reinstate the July 31 ban on common share dilution.

On July 31, 2025, Strategy provided clear guidance to its common shareholders: “We will not issue MSTR below 2.5x mNAV except to pay interest and dividends.”

Just two weeks later, on August 18, however, the company revised its promise to dilute MSTR “when otherwise deemed advantageous to the company.”

Strategy and Saylor have taken full advantage of that revoked guidance in the past six weeks. Specifically, the company has diluted MSTR common shareholders by 3,278,660 shares in order to spend $1,132,700,000 buying about 10,010 BTC

Although Strategy is a BTC treasury company valued based on its ability to accrete BTC for shareholders, those dilutive purchases haven’t helped its stock outperform this benchmark.

Since its $363.60 closing price on August 18, MSTR has declined more than 10% as of publication time.

Over the same time period, BTC has only declined 2%.

In other words, MSTR underperformed BTC by an embarrassing 800 basis points since it reintroduced its dilutive, at-the-market (ATM) offerings.

  • From August 18-24, Strategy diluted MSTR by 875,301 shares for $309.9 million in net proceeds.
  • From August 26-September 1, MSTR diluted by 1,237,000 shares for $425.3 million in net proceeds.
  • During September 2-7, Strategy diluted MSTR with another 591,606 shares for $200.5 million in net proceeds.
  • From September 8-21, the company diluted MSTR by 227,401 shares for $80.6 million in net proceeds.
  • Most recently, the company disclosed 347,352 shares for $116.4 million in net proceeds from September 22-28.

Almost all of those proceeds went to buying BTC. Including the above MSTR dilution plus other fundraises such as preferred share sales, the company bought $356.9 million worth of BTC from August 18-24, $449.3 million from August 26-September 1, $217.4 million from September 2-7, $159.9 million from September 8-21, and $22.1 million from September 22-28.

Read more: Michael Saylor continues to dilute MSTR after modifying promise

MSTR dilution paid for 94% of BTC purchases since August 18

On August 18, Strategy held 629,376 BTC. Today, it holds 640,031. MSTR dilution paid for most of that.

MSTR dilution funded $1,132,700,000 or 94% of the company’s total $1,205,600,000 worth of BTC purchases since August 18.

All of these sales were within the 1-2.5x multiple-to-Net Asset (mNAV) trading range for MSTR that Strategy’s July 31 promise explicitly forbade until the company abandoned that promise on August 18.

Indeed, MSTR has hasn’t traded outside of a 1-2.5x mNAV range since December 2024.

Interestingly, the company’s most recent, September 22-28 fundraise doesn’t seem to be fully expended on BTC purchases. Once these purchases are finished, if the company plans to buy more, this ratio could change slightly.

Unlike all of the prior fundraises where nearly the full amount of proceeds went to buying BTC, the company has only spent 17.2% of its $128.1 in net proceeds from September 22-28 buying BTC.

Of course, the company has quarterly dividend obligations to preferred shareholders, so it might not have enough cash to buy any more BTC. If so, that would leave the above 94% figure unchanged.

For just two weeks in August, MSTR shareholders were protected from the relentless dilution of Strategy leadership.

Since the company reintroduced MSTR dilution, its common share count has ballooned 1.2% while underperforming its BTC benchmark by 800 basis points.

Got a tip? Send us an email securely via Protos Leaks. For more informed news, follow us on X, Bluesky, and Google News, or subscribe to our YouTube channel.

Source: https://protos.com/94-of-strategys-bitcoin-buys-since-august-were-from-diluting-mstr/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

a16z Targets $2 Billion Crypto Fund as Venture Capital Eyes Blockchain Recovery

a16z Targets $2 Billion Crypto Fund as Venture Capital Eyes Blockchain Recovery

Andreessen Horowitz’s crypto division, a16z crypto, is reportedly running $2 billion for its fifth crypto investment fund. This move from a firm is happening when
Share
Thenewscrypto2026/03/05 20:29
ArtGis Finance Partners with MetaXR to Expand its DeFi Offerings in the Metaverse

ArtGis Finance Partners with MetaXR to Expand its DeFi Offerings in the Metaverse

By using this collaboration, ArtGis utilizes MetaXR’s infrastructure to widen access to its assets and enable its customers to interact with the metaverse.
Share
Blockchainreporter2025/09/18 00:07
Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Share
BitcoinEthereumNews2025/09/18 03:11